Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:RZLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRZLTRezolute$2.86-19.2%$2.10$0.72▼$3.69$114.77M1.29312,043 shs939,517 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRZLTRezolute+3.21%+14.94%+77.00%+247.06%+85.34%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRZLTRezolute3.3156 of 5 stars3.53.00.00.03.14.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRZLTRezolute3.00Buy$8.80207.69% UpsideCurrent Analyst RatingsLatest RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/14/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRZLTRezolute-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)Latest RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/13/2024Q2 2024RZLTRezolute-$0.27-$0.27N/A-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRZLTRezoluteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRZLTRezoluteN/A12.0012.00OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipRZLTRezolute18.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableRZLTRezolute5740.13 million32.83 millionNot OptionableRZLT HeadlinesSourceHeadlinePhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meetingglobenewswire.com - April 23 at 8:00 AMRezolute (NASDAQ:RZLT) Now Covered by Jonestradingamericanbankingnews.com - April 20 at 4:42 AMRezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by JMP Securitiesamericanbankingnews.com - April 20 at 1:54 AMJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy Recommendationmsn.com - April 19 at 8:15 AMRezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP Securitiesmarketbeat.com - April 18 at 2:21 PMJonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)marketbeat.com - April 18 at 8:35 AMOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospectsmarkets.businessinsider.com - April 18 at 5:30 AMCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?investorplace.com - April 15 at 3:43 PMRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 10 at 4:10 PMRezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim Groupmarketbeat.com - April 9 at 8:23 AMInsiders Are Buying These 5 Penny Stocksinsidermonkey.com - April 4 at 8:51 AMRezolute, Inc. (NASDAQ:RZLT) Short Interest Updatemarketbeat.com - March 27 at 9:30 PMRezolute Reaches US$75m Market Cap Benefiting Insider Stock Buyingfinance.yahoo.com - March 27 at 8:51 AM3 Stocks Insiders Are Buying That Analysts Love (RZLT)insidertrades.com - March 26 at 12:55 PMRezolute's chief medical officer buys $18.8k in company stockinvesting.com - March 20 at 5:29 PMDaron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stockinsidertrades.com - March 20 at 7:32 AMBrian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stockinsidertrades.com - March 19 at 5:40 AMInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of Stockinsidertrades.com - March 15 at 11:42 AMRezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in Stockinsidertrades.com - March 11 at 7:22 AMRezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)globenewswire.com - March 6 at 7:30 AMRezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning Callsbenzinga.com - February 22 at 12:13 PMRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Updatefinanznachrichten.de - February 16 at 9:03 AMWe're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Ratefinance.yahoo.com - February 15 at 7:59 AMRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Updatefinance.yahoo.com - February 13 at 7:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsRezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
